tiprankstipranks
Trending News
More News >

PharmaMar Reports Strong Q1 2025 Financial Growth

Story Highlights
PharmaMar Reports Strong Q1 2025 Financial Growth

Confident Investing Starts Here:

Pharma Mar SA ( (ES:PHM) ) has shared an update.

PharmaMar Group reported a 19% increase in recurring income, reaching 37.8 million euros in Q1 2025, driven by strong sales of lurbinectedin in Europe and the U.S. The company also saw a 22% rise in net sales and a 16% increase in royalty income. Despite a decrease in R&D investment, the financial results reflect positive growth in the oncology segment, with implications for sustained market presence and stakeholder confidence.

More about Pharma Mar SA

PharmaMar SA is a pharmaceutical company specializing in the development and commercialization of oncology drugs. Its primary products include Zepzelca® (lurbinectedin) and Yondelis® (trabectedin), with a strong market focus in Europe and the U.S.

YTD Price Performance: 11.88%

Average Trading Volume: 1,304

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.56B

See more insights into PHM stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App